君實/禮來新冠中和抗體雞尾酒療法在美國恢復分發
格隆匯8月28日丨美國禮來官網27日發佈聲明稱,美國監管部門已經恢復其與君實合作的抗體雞尾酒療法bamlanivimab/etesevimab的運輸和分銷。聲明提到,德爾塔變異株目前佔所有已識別變體的近96%,多項研究表明bamlanivimab和etesevimab共同用藥保留了對包括德爾塔變異株在內的中和活性。據悉,與君實合作的新冠中和抗體在2020年為禮來帶來了8.71億美元的收入,在2021Q1繼續增長,實現8.1億美元收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.